Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 834
  • Home
  • Print this page
  • Email this page


 
   Table of Contents      
BRIEF COMMUNICATION
Year : 2011  |  Volume : 59  |  Issue : 5  |  Page : 394-396

Combination therapy of low-fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane in choroidal osteoma


Department of Retina and Vitreous, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore - 641 014, Tamilnadu, India

Date of Submission04-Nov-2009
Date of Acceptance23-Sep-2010
Date of Web Publication9-Aug-2011

Correspondence Address:
Rodney J Morris
Department of Retina and Vitreous, Aravind Eye Hospital, Avinashi Road, Coimbatore- 641 014, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.83622

Rights and Permissions
  Abstract 

Choroidal osteoma is an unusual form of intraocular calcification seen in otherwise healthy eyes. It is a benign idiopathic osseous tumor of the choroid, typically seen in young females. Choroidal neovascular membrane (CNVM) is a complication seen in one-third of these patients and carries a poor visual outcome. We report a case of a 25-year-old hyperthyroid female with choroidal osteoma and subfoveal CNVM in her left eye which was successfully treated using low-fluence photodynamic therapy (PDT) with verteporfin followed by a single injection of intravitreal ranibizumab.

Keywords: Low-fluence photodynamic therapy, choroidal neovascular membrane, choroidal osteoma, ranibizumab


How to cite this article:
Morris RJ, Prabhu VV, Shah PK, Narendran V. Combination therapy of low-fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane in choroidal osteoma. Indian J Ophthalmol 2011;59:394-6

How to cite this URL:
Morris RJ, Prabhu VV, Shah PK, Narendran V. Combination therapy of low-fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane in choroidal osteoma. Indian J Ophthalmol [serial online] 2011 [cited 2019 Jul 17];59:394-6. Available from: http://www.ijo.in/text.asp?2011/59/5/394/83622

Choroidal osteoma is a rare, benign ossifying tumor of the choroid of unknown etiology, seen in healthy young females in the second or third decade of life. [1] The tumor is unilateral in 75% of cases and is located in a juxtapapillary or peripapillary location. Rarely, it is confined to the macula only. [2]

It is yellowish-white in color, relatively flat (up to 2.5 mm thick), around 2-22 mm in basal dimensions, and round or oval in shape with geographic or scalloped edges. [3]

Growth, decalcification, subretinal fluid, hemorrhage, and choroidal neovascular membrane (CNVM) are known complications of choroidal osteoma. CNVM is seen in one-third of patients [4] and is a major cause of visual impairment.

The cause for CNVM is speculative but it is postulated that neovascular fronds from choroid grow through the thinned degenerated Retinal Pigment Epithelium (RPE)-Bruch's membrane complex overlying the osteoma. [5] Argon laser photocoagulation is difficult due to lack of melanin in the tumor, and also, the potential for hemorrhage and disciform scarring is more.

In this case report, we present a case of a young female patient presenting with unilateral osteoma with secondary CNVM treated with combination therapy of low-fluence photodynamic therapy (PDT), followed by a single injection of intravitreal ranibizumab.


  Case Report Top


A 25-year-old lady presented with progressive defective vision in the Left Eye (LE) of 3-month duration. She was a known case of hyperthyroidism and was on medical treatment for the same. There was no history of any previous ocular trauma.

Ocular examination revealed best corrected visual acuity (BCVA) of 20/20 in the Right Eye (RE) and 20/80 in the LE. The pupillary reactions and slit-lamp biomicroscopic examination of the anterior segment were normal in both eyes. Fundus examination of the RE was normal, while the LE showed a yellowish-orange lesion of 1 disc diameter (DD) having well-defined scalloped margins with pseudopod extensions superiorly and subretinal hemorrhage in the fovea [Figure 1]a. Fundus fluorescein angiography (FFA) showed an area of delineation of around 1 DD in the foveal avascular zone. It also revealed a lacy pattern of early hyperfluorescence with leakage of dye in the late phase suggestive of classic CNVM along with blocked fluorescence temporally due to hemorrhage [Figure 1]b. RE was angiographically normal. Optical coherence tomography confirmed the presence of the subfoveal CNVM with fluid and central macular thickness (CMT) of 203 μm [Figure 1]c. B-scan ultrasonography showed a highly reflective mass lesion around 2 mm in basal dimension in the posterior pole and shadowing of orbital soft tissues posterior to the lesion. A-scan ultrasonography showed a high spike corresponding to the anterior surface of the lesion suggestive of choroidal osteoma [Figure 2]. Thus we came to a clinical diagnosis of choroidal osteoma with secondary subfoveal CNVM.
Figure 1: (a) Fundus photograph of the left eye showing yellowishorange lesion with scalloped margins and pseudopod borders and subretinal hemorrhage in fovea. (b) Late phase angiography shows intense leakage of the dye and blocked fl uorescence from hemorrhage suggestive of CNVM. (c) Oblique OCT scan showing subfoveal hyperreflectivity in the RPE layer with the fl uid suggestive of CNVM

Click here to view
Figure 2: Ultrasound B-scan showing hyperrefl ective mass lesion in the posterior pole (white arrow) with aftershadowing of orbital soft tissue posterior to it (black arrow) suggestive of choroidal osteoma

Click here to view


Subfoveal classic nature of CNVM prompted us to treat the patient with combination therapy, i.e., low-fluence PDT followed by an intravitreal injection of ranibizumab 48 h later. After an informed written consent and physician fitness, low-fluence PDT with a light dose 25 J/cm 2 , power 300 mw/cm 2 , exposure time of 83 s, and spot size of 3100 μm as per standard low-fluence specifications was given. Forty-eight hours post-PDT, 0.5 mg intravitreal ranibizumab (Lucentis; Novartis, India) was injected in the same eye under aseptic precautions. The patient was reviewed 4 weeks postinjection and her BCVA improved to 20/20. Fundus examination showed absorbed hemorrhage and resolved CNVM [Figure 3]a. FFA showed minimal hyperfluorescence with staining in the late phase suggestive of scarring [Figure 3]b. OCT showed that CMT reduced to 166 μm with the resolved fluid [Figure 3]c. At 15-month follow-up, FFA showed regressed, scarred CNVM [Figure 4]a and OCT [Figure 4]b showed dry macula. She maintained the good vision.
Figure 3: (a) Fundus photograph of the same eye showing absorbed hemorrhage and resolved CNVM posttreatment. (b) Late phase angiogram showing an absence of leakage and staining of scar tissue
posttreatment. (c) Oblique OCT scan suggesting hyperrefl ectivity in the RPE layer and the absence of the fl uid indicating scarred CNVM posttreatment


Click here to view
Figure 4: (a) 15-month follow-up FFA showing scarred, inactive CNVM. (b) Horizontal transverse OCT scan showing scarred CNVM with normal foveal contour and absence of the fl uid

Click here to view



  Discussion Top


Forty-seven percent cases of choroidal osteoma develop CNVM by 10 years and 56% by 20 years. [4] It carries a dismal prognosis. PDT has successfully caused closure of extrafoveal CNVM in choroidal osteoma. [6] CNVM in osteoma is subretinal in location and PDT causes selective closure of CNVM (angio-occlusion) and acts independent of intrinsic pigmentation of the tumor. Using low fluence, we intend to cause minimal damage to overlying neurosensory retina, adjacent choriocapillaries, and thinned RPE-Bruch's membrane complex. Post-PDT, there is an upregulation of vascular endothelial growth factor (VEGF) and pigment epithelium derived factor (PEDF) which has varied implications. [7] PEDF limits hypoxia-induced retinal damage allowing surrounding choroidal vessel recovery and VEGF upregulation causes recurrent growth of CNVM beginning a week post-PDT. Multiple anti-VEGF injections have been reported to cause Bruch's membrane rupture in conditions where the Bruch's membrane is calcified and brittle. [8] Combination therapy reduces the number of anti-VEGF injections, hence reducing the risk of vision-threatening complications. Strategies to combat the post-PDT spike of VEGF increases effectiveness of PDT. Bevacizumab has shown to be an effective alternative to manage secondary CNVM in choroidal osteoma, [9] but it lacks Food and Drugs Administration (FDA)'s approval. Ranibizumab is a monoclonal antibody derived from the same parent murine antibody as bevacizumab and also FDA-approved for treatment of CNVM in wet age-related macular degeneration (AMD). It has been successfully used both as monotherapy and in combination with PDT in the treatment of CNVM secondary to AMD. [10] Combination therapy rationale of giving finitism to treatment along with a marked improvement in visual acuity without untoward effects following the treatment of the CNVM secondary to choroidal osteoma has been successfully documented in our case.

A detailed search and analysis of content in medical databases like Medline and Embase failed to reveal mention of any case study illustrating successful treatment of CNVM in choroidal osteoma with combination therapy of low-fluence PDT followed by a single dose of intravitreal ranibizumab. However, a larger prospective trial with a much longer follow-up will be required to reach conclusive results.

 
  References Top

1.
Chen J, Lee L, Gass JD. Choroidal osteoma: Evidence of progression and decalcification over 20 years. Clin Exp Optom. 2006;89:90-4.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.
Kadrmas EF, Weiter JJ. Choroidal osteoma. Int Ophthalmol Clin 1997;37:171-82.  Back to cited text no. 2
[PUBMED]    
3.
Shields CL, Shields JA, Augsburg JJ. Choroidal osteoma. Surv Ophthalmol 1988;33:17-27.   Back to cited text no. 3
    
4.
Aylward GW, Chang TS, Pautler SE, Gass JD. A long-term follow-up of choroidal osteoma. Arch Ophthalmol 1998;116:1337-41.  Back to cited text no. 4
[PUBMED]    
5.
Grand MG, Burgess DB, Singerman LJ, Ramsej J. Choroidal osteoma. Treatment of associated subretinal neovascular membranes. Retina 1984;4:80-4.  Back to cited text no. 5
    
6.
Battaglia Parodi M, Da Pozzo S, Toto L, Saviano S, Ravalico G. Photodynamic therapy for choroidal neovascularization associated with choroidal osteoma. Retina 2001;21:660-7.   Back to cited text no. 6
[PUBMED]  [FULLTEXT]  
7.
Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Naumann. Influence of Photodynamic Therapy on Expression of Vascular Endothelial Growth Factor (VEGF), VEGF Receptor 3, and Pigment Epithelium-Derived Factor. Invest Ophthalmol 2003;44:4473-80.  Back to cited text no. 7
    
8.
Sen PR, Rishi P, Sen P, Rishi E, Shroff D. Rapid progression of angioid streaks following intravitreal bevacizumab. Can J Ophthalmol 2009;44:p39-40.  Back to cited text no. 8
    
9.
Ahmadieh H, Vafi N. Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol. 2007;245:1731-3.  Back to cited text no. 9
[PUBMED]  [FULLTEXT]  
10.
Kumar A, Gopalakrishnan K, Sinha S. Combination photodynamic therapy and intravitreal ranibizumab in neovascular AMD in a north Indian population: A pilot study. Retina 2008;28:1132-7.  Back to cited text no. 10
[PUBMED]    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]


This article has been cited by
1 OUTCOMES OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN THE MANAGEMENT OF CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CHOROIDAL OSTEOMA
Mohammed A. Khan,Francis C. DeCroos,Philip P. Storey,Jerry A. Shields,Sunir J. Garg,Carol L. Shields
Retina. 2014; 34(9): 1750
[Pubmed] | [DOI]
2 Diagnosis and Monitoring of Choroidal Osteoma through Multimodal Imaging
Theodoros Empeslidis,Usman Imrani,Vasileios Konidaris,Fizza Mushtaq,Pandelis Fotiou,Periyasami Kumar,Somnath Banerjee,Konstantinos T. Tsaousis
Case Reports in Medicine. 2014; 2014: 1
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Abstract
Case Report
Discussion
References
Article Figures

 Article Access Statistics
    Viewed3471    
    Printed62    
    Emailed1    
    PDF Downloaded212    
    Comments [Add]    
    Cited by others 2    

Recommend this journal